Replimune Group (NASDAQ:REPL) Reaches New 12-Month High – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $14.14 and last traded at $13.65, with a volume of 4763199 shares traded. The stock had previously closed at $13.67.

Key Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million financing improves liquidity: Replimune priced a $150 million underwritten offering, providing additional capital to fund development of RP1 and its broader oncology pipeline. The financing reduces near-term funding concerns, although it will dilute existing shareholders. Replimune Announces Pricing of $150 Million Underwritten Offering
• Positive Sentiment: Analysts became more bullish: JPMorgan raised its price target to $20, while other firms upgraded or increased their targets, helping support investor sentiment. The broader analyst consensus remains below the recent trading range, however. Replimune Shares Rise After Pricing of Offering
• Neutral Sentiment: Insiders sold shares for tax withholding: The CEO, CFO, chief accounting officer and another insider collectively sold about 69,868 shares worth approximately $906,000. The filings said the transactions were used to cover taxes on vested equity awards, and the executives retained substantial holdings, limiting the negative signal. SEC insider transaction filing
• Negative Sentiment: Multiple law firms publicized a securities class action: The lawsuit alleges that Replimune misled investors about RP1’s efficacy, commercial readiness and unresolved FDA concerns. The allegations relate to securities purchased from October 20, 2025, through April 10, 2026, when shares fell after the FDA rejected the company’s application and said previously communicated study-design concerns had not been addressed. The lead-plaintiff deadline is October 5, 2026. The claims have not been proven, but the litigation creates legal, financial and reputational uncertainty. Replimune securities lawsuit notice

Wall Street Analyst Weigh In

REPL has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a report on Friday, August 7th. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research report on Tuesday, June 30th. Finally, JPMorgan Chase & Co. lifted their price objective on Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.86.

Replimune Group Stock Performance

The company has a market cap of $1.28 billion, a P/E ratio of -4.49 and a beta of 0.88. The company’s fifty day moving average is $10.55 and its 200 day moving average is $7.74. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities analysts predict that Replimune Group, Inc. will post -2.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 11,448 shares of Replimune Group stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,480.56. Following the transaction, the chief financial officer directly owned 225,108 shares of the company’s stock, valued at $2,919,650.76. The trade was a 4.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the sale, the chief accounting officer owned 99,425 shares of the company’s stock, valued at $1,289,542.25. The trade was a 7.13% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 81,868 shares of company stock worth $1,017,068 over the last quarter. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Large investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC bought a new stake in shares of Replimune Group in the 4th quarter worth approximately $29,000. Russell Investments Group Ltd. lifted its stake in Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after acquiring an additional 7,569 shares during the period. CWM LLC boosted its holdings in Replimune Group by 248.6% in the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares in the last quarter. Essential Partners LLC boosted its holdings in Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after purchasing an additional 6,873 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.